Literature DB >> 20336406

The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues.

Vesna Bucan1, Kerstin Reimers, Claudia Yu Choi, Mau-Thek Eddy, Peter M Vogt.   

Abstract

Lifeguard (LFG) is an anti-apoptotic protein that inhibits Fas-mediated death in tumour cells. However, the molecular function of human LFG in the carcinogenesis of human breast cells is uncertain. We studied the expression and function of endogenous LFG in four breast cancer cell lines (MCF-7, MDA-MB-231, T-47D and HS 578T), a human breast epithelial cell line (HS 578Bst), and in healthy and cancerous breast tissues. Molecular (Western blot and RT-PCR) and immunohistochemical techniques were used to investigate the LFG expression. To investigate the breast cancer cell proliferation in the presence of Fas, we performed fluorescent cell viability assays. The possible association of Fas with LFG was analyzed by immunofluorescence microscopy. In this paper, we provide convincing evidence that LFG is overexpressed in several human breast cancer cell lines. More importantly, we found that the LFG expression correlates with high tumour grades in primary breast tumours. Finally, we demonstrated that Fas sensitivity is reduced in breast cancer cell lines expressing LFG. Our results indicated that LFG is strongly expressed in breast cancer epithelial cells. Moreover, the overexpression of LFG correlated with tumour grade and reduced Fas sensitivity. Our findings support the idea that LFG may have a role in the downregulation of apoptosis in breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336406      PMCID: PMC6275920          DOI: 10.2478/s11658-010-0009-1

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  47 in total

1.  Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak.

Authors:  Simon N Willis; Jamie I Fletcher; Thomas Kaufmann; Mark F van Delft; Lin Chen; Peter E Czabotar; Helen Ierino; Erinna F Lee; W Douglas Fairlie; Philippe Bouillet; Andreas Strasser; Ruth M Kluck; Jerry M Adams; David C S Huang
Journal:  Science       Date:  2007-02-09       Impact factor: 47.728

2.  Down-regulation of bcl-2 by p53 in breast cancer cells.

Authors:  S Haldar; M Negrini; M Monne; S Sabbioni; C M Croce
Journal:  Cancer Res       Date:  1994-04-15       Impact factor: 12.701

3.  Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene.

Authors:  I Sturm; S Papadopoulos; T Hillebrand; T Benter; H J Lück; G Wolff; B Dörken; P T Daniel
Journal:  Int J Cancer       Date:  2000-08-15       Impact factor: 7.396

4.  Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells.

Authors:  Michal Grzmil; Silke Kaulfuss; Paul Thelen; Bernhard Hemmerlein; Stefan Schweyer; Silvia Obenauer; Tae Won Kang; Peter Burfeind
Journal:  J Pathol       Date:  2006-02       Impact factor: 7.996

Review 5.  Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  J Cell Biochem       Date:  2008-07-01       Impact factor: 4.429

6.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

Review 7.  Apoptotic pathways in tumor progression and therapy.

Authors:  Armelle Melet; Keli Song; Octavian Bucur; Zainab Jagani; Alexandra R Grassian; Roya Khosravi-Far
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

8.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.

Authors:  E Yang; J Zha; J Jockel; L H Boise; C B Thompson; S J Korsmeyer
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

9.  Bax inhibitor-1, a mammalian apoptosis suppressor identified by functional screening in yeast.

Authors:  Q Xu; J C Reed
Journal:  Mol Cell       Date:  1998-02       Impact factor: 17.970

10.  Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.

Authors:  S Esseghir; J S Reis-Filho; A Kennedy; M James; M J O'Hare; R Jeffery; R Poulsom; C M Isacke
Journal:  J Pathol       Date:  2006-12       Impact factor: 7.996

View more
  9 in total

1.  Transmembrane BAX inhibitor motif containing (TMBIM) family proteins perturbs a trans-Golgi network enzyme, Gb3 synthase, and reduces Gb3 biosynthesis.

Authors:  Toshiyuki Yamaji; Kiyotaka Nishikawa; Kentaro Hanada
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

2.  Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumor cell lines MCF-7 and SW872 to perifosine-induced cell death activation.

Authors:  Vesna Bucan; Claudia Y U Choi; Andrea Lazaridis; Peter M Vogt; Kerstin Reimers
Journal:  Oncol Lett       Date:  2011-03-21       Impact factor: 2.967

Review 3.  TMBIM protein family: ancestral regulators of cell death.

Authors:  D Rojas-Rivera; C Hetz
Journal:  Oncogene       Date:  2014-02-24       Impact factor: 8.756

4.  TRIM21, a negative modulator of LFG in breast carcinoma MDA-MB-231 cells in vitro.

Authors:  Judith Müller; Viktor Maurer; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Int J Oncol       Date:  2015-09-16       Impact factor: 5.650

5.  Role of lifeguard β-isoform in the development of breast cancer.

Authors:  Nadjib Dastagir; Andrea Lazaridis; Khaled Dastagir; Kerstin Reimers; Peter M Vogt; Vesna Bucan
Journal:  Oncol Rep       Date:  2014-07-25       Impact factor: 3.906

Review 6.  Golgi anti-apoptotic protein: a tale of camels, calcium, channels and cancer.

Authors:  Guia Carrara; Maddy Parsons; Nuno Saraiva; Geoffrey L Smith
Journal:  Open Biol       Date:  2017-05       Impact factor: 6.411

7.  Thy28 partially prevents apoptosis induction following engagement of membrane immunoglobulin in WEHI-231 B lymphoma cells.

Authors:  Hiroko Toyota; Xiao-Zhou Jiang; Hideki Asakura; Junichiro Mizuguchi
Journal:  Cell Mol Biol Lett       Date:  2011-12-02       Impact factor: 5.787

8.  In-Vitro Application of Magnetic Hybrid Niosomes: Targeted siRNA-Delivery for Enhanced Breast Cancer Therapy.

Authors:  Viktor Maurer; Selin Altin; Didem Ag Seleci; Ajmal Zarinwall; Bilal Temel; Peter M Vogt; Sarah Strauß; Frank Stahl; Thomas Scheper; Vesna Bucan; Georg Garnweitner
Journal:  Pharmaceutics       Date:  2021-03-16       Impact factor: 6.321

9.  Landscape of Bone Marrow Metastasis in Human Neuroblastoma Unraveled by Transcriptomics and Deep Multiplex Imaging.

Authors:  Daria Lazic; Florian Kromp; Fikret Rifatbegovic; Peter Repiscak; Michael Kirr; Filip Mivalt; Florian Halbritter; Marie Bernkopf; Andrea Bileck; Marek Ussowicz; Inge M Ambros; Peter F Ambros; Christopher Gerner; Ruth Ladenstein; Christian Ostalecki; Sabine Taschner-Mandl
Journal:  Cancers (Basel)       Date:  2021-08-26       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.